American Academy of Allergy, Asthma & Immunology

The FDA previously approved DUPIXENT in the US for the treatment of adults with moderate-to-severe atopic dermatitis.

The phase 3b MUSCA trial reported positive results for mepolizumab.

Jay Jin, MD, PhD, Mayo Clinic, shared the results from his team's case series surrounding unexpected bradycardia effect from epinephrine administration.

Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases (NIAID), shared with MD Magazine what the main theme would be in his keynote address at the AAAAI 2017 meeting in Atlanta, GA: emerging and reemerging infections, a perpetual challenge.

Only a small percentage of people who think they have a penicillin allergy actually do.

How safe are anti-inflammatory medications for children?

A chlamydia vaccine would cut infection rates, but cost millions.

In the inner cities some children do not have the resources at their disposal to get the care they needed. Recently considerable effort has been made to helping keep them healthy and able to function in their daily lives.

Clinicians have several options when it comes to treating their allergic patients with subcutaneous (SCIT) or sublingual (SLIT) immunotherapy.

Clinicians have several guidelines, algorithms, and other tools at their disposal that can assist them in the differential diagnosis and management of chronic urticaria.

The skin microbiome may have beneficial influence on the skin through three mechanisms: direct inhibition of pathogen growth, improvement of the host's immune system, and education and priming of the adaptive immune system

Successful applications of nanotechnology in the field of immunology will enable new generations of vaccines, adjuvants, and immunomodulatory drugs that aim to improve clinical outcomes in response in a range of infectious and non-infectious diseases.

With reimbursement increasingly tied to quality measures and other metrics, the question of whether best practices actually produce improved outcomes has taken on greater importance for clinicians and their patients.

New research suggests that patients with allergic rhinitis face significantly lower risks for heart attacks, cerebrovascular disease, and all-cause mortality.